ArticleScientific reports2025
New candidate gene mutations in astrocytoma with seizures.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Seizures are a common presenting symptom in astrocytomas, yet the underlying genomic drivers remain incompletely understood. We performed whole-exome sequencing on tumor tissue from 40 patients with astrocytoma (25 with preoperative seizures, 15 without) to explore somatic mutation profiles associated with seizure occurrence. Clinical characteristics, including age, tumor location, volume, and IDH mutation status, did not significantly differ between seizure and non-seizure groups. In the overall cohort, nine genes showed nominal associations with seizures, but none remained significant following correction for multiple comparisons. Stratification by IDH status revealed that CELSR1 mutations were significantly enriched in the seizure group among IDH-wildtype astrocytomas/glioblastomas (6/19 [31.6%] vs. 0/10 [0%], p = 0.028, OR = ∞), whereas GSTT4 and other candidate genes lost association in subgroup analyses. CELSR1, a core component of the planar cell polarity pathway, represents a novel candidate gene potentially contributing to tumor-associated epilepsy in IDH-wildtype disease. These findings highlight the importance of molecular subgrouping and warrant validation in larger cohorts and functional studies of CELSR1 in epileptogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.